Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
Alexandria Medical Journal [The]. 2006; 48 (4): 556-566
in English | IMEMR | ID: emr-75746

ABSTRACT

Hepatocellular carcinoma [HCC] represents a major health problem world wide. It accounts for 90% of all primary liver cancers and is the fifth most common malignancy [1]. Evaluation of radiofrequency thermal ablation versus transarterial hepatic chemoembolization with the effect of Viscum [Fraxini 2] on tumour recurrence. 60 patients with HCC were enrolled in the study. Group 1 include 30 patients and were treated with radiofrequency thermal ablation [15 patients of them received viscum 2 by subcutaneous route for 2 years]. Group 11 included 30 patients with HCC and were treated by TACE [15 patients of them received viscum 2 subcutaneously for 2 years]. Group 1 patients showed total ablation in 70% with persistant inactivity during 2 years follow up. Group II did not show significant difference from Group 1 as regards relapse rate nor the performance status. Complications as nausea, vomiting, fever, jaundice, and elevation of transaminases were significantly more encountered with TA CE. Viscum 2 did not significantly arrest tumour recurrence. Non surgical patients with HCC can achieve curative treatment with radiofrequency with minimal side effects. TACE is a palliative treatment option for large HCC


Subject(s)
Humans , Male , Female , Catheter Ablation , Chemoembolization, Therapeutic , Comparative Study , Follow-Up Studies , Mistletoe/drug effects , Treatment Outcome , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL